文献速递浆细胞疾病

每周两次伊沙佐米联合来那度胺-地塞米松治疗新诊断多发性骨髓瘤患者

Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.
PubMed 文献 · Br J Haematol · 2018-06-25

这项1/2期研究评估了每周两次伊沙佐米联合来那度胺-地塞米松(Rd)在新诊断多发性骨髓瘤(NDMM)中的推荐2期剂量(RP2D)、药代动力学、安全性和有效性,共纳入64例患者。结果显示,确认的总缓解率为94%(≥非常好的部分缓解68%;完全缓解24%),中位无进展生存期为24.9个月。每周两次伊沙佐米-Rd方案在该人群中显示出显著活性且长期结局良好,但与每周一次伊沙佐米-Rd相比可能毒性更大。

要点

  • 在62例可评估患者中,确认的总缓解率为94%,其中≥非常好的部分缓解为68%,完全缓解为24%。
  • 中位无进展生存期为24.9个月;接受RP2D的患者中位缓解持续时间为36.9个月。
  • 3级药物相关不良事件发生率为64%,包括皮疹13%、周围神经病变8%、高血糖8%;无4级药物相关不良事件。

核心结论

  • 每周两次伊沙佐米-Rd在新诊断多发性骨髓瘤患者中显示出显著活性且长期结局良好,但与每周一次伊沙佐米-Rd相比可能毒性更大。

研究设计与样本

  • 1/2期研究(NCT01383928),评估每周两次伊沙佐米联合来那度胺-地塞米松的推荐2期剂量、药代动力学、安全性和有效性。
  • 共纳入64例新诊断多发性骨髓瘤患者,两个阶段合计。
  • 患者接受每周两次口服伊沙佐米3.0或3.7 mg联合来那度胺25 mg和地塞米松20 mg(第9-16周期为10 mg),最多16个21天周期,随后接受每周两次伊沙佐米单药维持治疗。

主要发现

  • 第1周期未报告剂量限制性毒性;基于多个周期的总体耐受性,推荐2期剂量为3.0 mg。
  • 在62例可评估患者中,确认的总缓解率为94%(≥非常好的部分缓解68%;完全缓解24%)。
  • 中位无进展生存期为24.9个月;接受RP2D的患者中位缓解持续时间为36.9个月,缓解在治疗期间加深。
  • 3级药物相关不良事件发生于64%的患者,包括皮疹13%、周围神经病变8%、高血糖8%;无4级药物相关不良事件。
  • 13例患者因不良事件终止治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Weekly ixazomib with lenalidomide-dexamethasone (Rd) is feasible and has shown activity in newly diagnosed multiple myeloma (NDMM) patients. This phase 1/2 study (NCT01383928) evaluated the recommended phase 2 dose (RP2D), pharmacokinetics, safety and efficacy of twice-weekly ixazomib plus Rd in NDMM; 64 patients were enrolled across both phases. Patients received twice-weekly oral ixazomib 3·0 or 3·7 mg plus lenalidomide 25 mg and dexamethasone 20 mg (10 mg in cycles 9-16) for up to sixteen 21-day cycles, followed by maintenance with twice-weekly ixazomib alone. No dose-limiting toxicities were reported in cycle 1; the RP2D was 3·0 mg based on overall tolerability across multiple cycles. In 62 evaluable patients, the confirmed overall response rate was 94% (68% ≥very good partial response; 24% complete response). Median progression-free survival was 24·9 months. Responses (median duration 36·9 months for patients receiving the RP2D) deepened during treatment. Grade 3 drug-related adverse events (AEs) occurred in 64% of patients, including: rash, 13%; peripheral neuropathy, 8%; hyperglycaemia, 8%. There were no grade 4 drug-related AEs. Thirteen patients discontinued due to AEs. Twice-weekly ixazomib-Rd offers substantial activity with promising long-term outcomes in NDMM patients but may be associated with greater toxicity compared with weekly ixazomib-Rd in this setting.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Richardson PG, Hofmeister CC, Rosenbaum CA, et al. Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. Br J Haematol. 2018. PMID: 29938772. doi:10.1111/bjh.15394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。